The Readout Loud
STAT
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Episodes
Mentioned books
Sep 20, 2018 • 25min
Episode 29: A Hong Kong heat-check, a $20 million wrist slap, and pharma's (other) diversity problem
Is a biotech bubble inflating in China? Do the feds coddle CEOs? And why don't clinical trials look like America?
Sep 13, 2018 • 23min
Episode 28: Founders' funds, doctors' disclosures, and the subtle art of beeping
Is biotech too founder-friendly? Is honesty overrated? And how do you tell a good beep from a bad one?
Sep 6, 2018 • 26min
Episode 27: Live from Boston!
Should genome editors be worried? Has 2018 been a bummer? And are voters ready to love Big Pharma? We discuss this and more on a special live episode from the BioPharm America conference in Boston.
Aug 30, 2018 • 18min
Episode 26: FDA shows its teeth, biotech fish oil might be pointless, & treating McCain's cancer
Is the FDA as lenient as everyone thinks? Can fish oil be a multibillion-dollar drug? And why aren't there better treatments for brain cancer?
Aug 23, 2018 • 22min
Episode 25: A genome-editing first, Trump on Wall Street, and biotech red flags
Can genome-editing work in actual people? Are CEOs oversharing? And how do you sniff out a bad bet before it happens?
Aug 16, 2018 • 24min
Episode 24: A lesson in startup jargon, pharma's bare Alzheimer's cupboard, and the cost of CAR-T
How much is a shot at curing cancer worth? Where are all the drugs for late-stage Alzheimer's disease? And what on Earth is an "oversubscribed Series A round"?
Aug 9, 2018 • 21min
Episode 23: Congressional insider trading, PETA and fake meat, & doctors vs. fund managers
Can insider trading charges derail political campaigns? Should you trust a fund manager over a doctor? And how many rats would you trade for a cow?
Aug 2, 2018 • 23min
Episode 22: Biotech's battle for talent, Sanofi's second act, and climbing Mt. Everest
What juicy perks do biotech startups offer to lure increasingly hard-to-find talent? How does Sanofi plan to make up for lost time in the lucrative field of oncology? And veteran biotech journalist Luke Timmerman talks about what it's like to climb Mt. Everest.
Jul 26, 2018 • 25min
Episode 21 - A debatable Alzheimer's breakthrough, Gilead's golden age, and "robust" data
What qualifies as "robust" when it comes to data? Is digital health a bubble? And can Gilead Sciences survive without men named John?
Jul 19, 2018 • 26min
Episode 20 - CRISPR freakouts, drug prices meet elections, and a busy earnings season
Can drug prices swing an election? Is every quarter a “great quarter“? And why is everyone freaking out about CRISPR? Listen, and all will be explained.
